Adam M. Chaker

Adam M. Chaker

Auto-generated profile, based on publicly available information

Adam M. Chaker

Department of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine and Health, TUM University Hospital, Klinikum Rechts der Isar Technical University of Munich Munich Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
CBClaus Bachert
Claus Bachert
ASAna R. Sousa
Ana R. Sousa
JHJoseph K. Han
Joseph K. Han
RSRodney J. Schlosser
Rodney J. Schlosser
LSLeigh J. Sowerby
Leigh J. Sowerby
ACAdam M. Chaker
Adam M. Chaker
In the phase III SYNAPSE study, mepolizumab reduced nasal polyp (NP) size and nasal obstruction in chronic rhinosinusitis with NP. We sought to assess the efficacy of mepolizumab in patients from SYNAPSE grouped by comorbid asthma, aspirin-exacerbated respiratory disease (AERD), and baseline blood eosinophil count (BEC). SYNAPSE, a randomized, double-blind, 52-week study (NCT03085797), included patients with severe bilateral chronic rhinosinusitis with NP eligible for surgery despite intranasal corticosteroid treatment. Patients received 4-weekly subcutaneous mepolizumab 100 mg or placebo plus standard of care for 52 weeks. Coprimary end points were change in total endoscopic NP score (week 52) and nasal obstruction visual analog scale score (weeks 49-52). Subgroup analyses by comorbid asthma and AERD status, and post hoc by BEC, were exploratory. Analyses included 407 patients (289 with asthma; 108 with AERD; 371 and 278 with BEC counts ≥150 or ≥300 cells/μL, respectively). The proportion of patients with greater than or equal to 1-point improvement from baseline in NP score was higher with mepolizumab versus placebo across comorbid diseases (asthma: 52.9% vs 29.5%; AERD: 51.1% vs 20.6%) and baseline BEC subgroups (<150 cells/μL: 55.0% vs 31.3%; ≥150 cells/μL: 49.5% vs 28.1%; <300 cells/μL: 50.7% vs 29.0%; ≥300 cells/μL: 50.4% vs 28.1%). A similar trend was observed in patients without comorbid asthma or AERD. More patients had more than 3-point improvement in nasal obstruction VAS score with mepolizumab versus placebo across comorbid subgroups. Mepolizumab reduced polyp size and nasal obstruction in chronic rhinosinusitis with NP regardless of the presence of comorbid asthma or AERD.

3 February 2023 in Allergy
Verified
Journal Article
Closed access
PGPhilippe Gevaert
Philippe Gevaert
JCJarno De Craemer
Jarno De Craemer
CBClaus Bachert
Claus Bachert
MBManon Blauwblomme
Manon Blauwblomme
ACAdam Chaker
Adam Chaker
IAIsam Alobid
Isam Alobid

1 October 2018 in EBioMedicine
Verified
Journal Article
Open access
UZUlrich M. Zissler
Ulrich M. Zissler
CJConstanze A. Jakwerth
Constanze A. Jakwerth
FGFerdinand M. Guerth
Ferdinand M. Guerth
LPLisa Pechtold
Lisa Pechtold
JAJuan Antonio Aguilar-Pimentel
Juan Antonio Aguilar-Pimentel
ACAdam M. Chaker
Adam M. Chaker

18 December 2023 in Allergy
Verified
Journal Article
Open access
PHPeter W. Hellings
Peter W. Hellings
IAIsam Alobid
Isam Alobid
WAWilma T. Anselmo‐Lima
Wilma T. Anselmo‐Lima
MBManuel Bernal‐Sprekelsen
Manuel Bernal‐Sprekelsen
LBLeif Bjermer
Leif Bjermer
WFW. J. Fokkens
W. J. Fokkens
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.

22 April 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MJMarta de Los Reyes Jiménez
Marta de Los Reyes Jiménez
ALAntonie Lechner
Antonie Lechner
FAFrancesca Alessandrini
Francesca Alessandrini
SBSina Bohnacker
Sina Bohnacker
SSSonja Schindela
Sonja Schindela
JBJulia Esser-Von Bieren
Julia Esser-Von Bieren
A helminth larval extract and its component Hpb glutamate dehydrogenase induce an anti-inflammatory mediator switch to suppress type-2 inflammation.

19 October 2020 in Allergy
Verified
Journal Article
Open access
PDF file
LKLudger Klimek
Ludger Klimek
Marek JutelMarek Jutel
Marek Jutel
JBJean Bousquet
Jean Bousquet
IAIoana Agache
Ioana Agache
CACezmi A. Akdis
Cezmi A. Akdis
WFWytske Fokkens
Wytske Fokkens
Background: Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID‐19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type‐2 (T2) inflammation endotypes.Methods: The current knowledge on COVID‐19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet.Results: Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID‐19 pandemic.Conclusion: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS‐CoV‐2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID‐19 infection.